Related references
Note: Only part of the references are listed.Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen Fernandez et al.
JAMA ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Caterina Marchio et al.
SEMINARS IN CANCER BIOLOGY (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
The Exciting New Field of HER2-Low Breast Cancer Treatment
Daniel Eiger et al.
CANCERS (2021)
HER2 Molecular Marker Scoring Using Transfer Learning and Decision Level Fusion
Suman Tewary et al.
JOURNAL OF DIGITAL IMAGING (2021)
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues
Jacob J. Kennedy et al.
CLINICAL CHEMISTRY (2021)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley et al.
LANCET ONCOLOGY (2021)
Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study
Meng Yue et al.
VIRCHOWS ARCHIV (2021)
Molecular Classification of Breast Cancer
Julia Y. S. Tsang et al.
ADVANCES IN ANATOMIC PATHOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH
Carlos Castera et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2020)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues
Talha Qaiser et al.
HISTOPATHOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations
Wedad M. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers
Kathleen Lambein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Distinguishing Score 0 From Score 1+in HER2 Immunohistochemistry-Negative Breast Cancer Clinical and Pathobiological Relevance
Kathleen Lambein et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations
Kathleen Lambein et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed
Timothy D'Alfonso et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
What Causes Discrepancies in HER2 Testing for Breast Cancer? A Japanese Ring Study in Conjunction With the Global Standard
Shinobu Umemura et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Answering the Call for a Standard Reliability Measure for Coding Data
Andrew F. Hayes et al.
COMMUNICATION METHODS AND MEASURES (2007)
HER-2/neu in breast cancer:: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization
TA Thomson et al.
MODERN PATHOLOGY (2001)
Share Paper
